Albireo is an independent Swedish biotechnology company, which brings unique translational approaches to develop drugs that fulfil unmet medical needs in the gastrointestinal (GI) and liver disease areas. The team has a broad experience in drug development, primarily in the GI area and has an extensive network in the international scientific and clinical communities.
Albireo’s Lead Compound in Cholestatic Liver Diseases, A4250, Protects Against Bile Acid-Mediated Cholestatic Liver Injury In Mice
Albireo has Initiated a Clinical Study Using A3384 in Patients with Bile Acid Malabsorption
Go to news archive
JP Morgan, San Francisco, January 12-15 2015